A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines

Biotechnology Progress

Volumn 27, Issue 3, 2011, Pages 766-775

  Rossi, Diane L ^a   Rossi, Edmund A ^b   Goldenberg, David M ^c   Chang, Chien Hsing ^a,b  

^a IMMUNOMEDICS INC   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Bcl2; Host cell line; Monoclonal antibody; Myeloma cell culture; Protein expression

Indexed keywords

ANIMAL PRODUCTS; BCL2; CELL DENSITY; CELL LINES; CELL SURVIVAL; CONSTITUTIVELY ACTIVES; CRYO-PRESERVATION; DEVELOPMENT PROCESS; GROWTH PROPERTIES; HIGH COSTS; HOST CELLS; MAMMALIAN HOSTS; MONOCLONAL ANTIBODIES (MABS); MYELOMA CELL; MYELOMA CELL LINE; PRODUCTION CELLS; PROTEIN EXPRESSION; PROTEIN PRODUCTION; ROBUST GROWTH; SAFETY CONCERNS; SERUM-INDEPENDENT GROWTH; SODIUM BUTYRATE; SUBCLONING; TRANSFECTANTS; TRANSFECTION EFFICIENCY;

AMINO ACIDS; ANIMAL CELL CULTURE; CELL DEATH; CLONING; MAMMALS; MONOCLONAL ANTIBODIES; PRODUCTIVITY; SODIUM; SURFACE PLASMON RESONANCE;

BODY FLUIDS;

MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CLONE; CELL SURVIVAL; CULTURE MEDIUM; GENETIC TRANSFECTION; GENETICS; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL SURVIVAL; CLONE CELLS; CULTURE MEDIA, SERUM-FREE; MICE; TRANSFECTION;

ANIMALIA; MAMMALIA;

EID: 79958283447     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.584     Document Type: Article

References (39)

1. Walsh G. Biopharmaceutical benchmarks-2006. Nat Biotechnol. 2006; 24: 769-776.
2. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs. 2009; 1: 443-452.
3. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, van der Helm E, Smits S, Schouten J, Brouwer K, Lagerwerf F, van Berkel P, Opstelten DJ, Logtenberg T, Bout A. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol Prog. 2003; 19: 163-168.
4. Dickson AJ. Apoptosis regulation and its applications to biotechnology. Trends Biotechnol. 1998; 16: 339-342.
5. Fussenegger M, Bailey JF. Molecular regulation of cell-cycle progression and apoptosis in mammalian cells: implications for biotechnology. Biotechnol Prog. 1998; 14: 807-833.
6. Singh RP, Al-Rubeai M. Apoptosis and bioprocess technology. Adv Biochem Eng Biotechnol. 1998; 62: 167-184.
7. Itoh Y, Ueda H, Suzuki E. Overexpression of bcl-2, apoptosis suppressing gene: prolonged viable culture period of hybridoma and enhanced antibody production. Biotechnol Bioeng. 1995; 48: 118-122.
8. Simpson N, Milner AN, Al-Rubeai M. Prevention of hybridoma cell death by bcl-2 during sub-optimal culture conditions. Biotechnol Bioeng. 1997; 54: 1-16.
9. Meents H, Burtrum D, Petrie HT. Regulation of cell division cycle progression by Bcl2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med. 1996; 183: 2219-2226.
10. Tey BT, Singh RP, Piredda L, Piacentini M, Al-Rubeai M. Influence of Bcl2 on cell death during the cultivation of a Chinese hamster ovary cell line expressing a chimeric antibody. Biotechnol Bioeng. 2000; 68: 31-43.
11. L variant to the wild-type anti-apoptosis inhibitor in mammalian cell cultures. Metab Eng. 2003; 5: 230-245.
12. Figueroa B, Jr, Sauerwald TM, Mastrangelo AJ, Hardwick JM, Betenbaugh MJ. Comparison of Bcl2 to a Bcl2 deletion mutant for mammalian cells exposed to culture insults. Biotechnol Bioeng. 2001; 73: 211-222.
13. Chang B, Minn A, Muchmore S, Fesik S, Thompson C. Identification of a novel regulatory domain in Bcl-XL and Bcl2. EMBO J. 1997; 16: 968-977.
14. Deng X, Gao F, Flagg T, May WS, Jr. Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. PNAS. 2004; 101: 153-158.
15. Dorai H, Kyung YS, Ellis D, Kinney C, Lin C, Jan D, Moore G, Betenbaugh MJ. Expression of anti-apoptosis genes alters lactate metabolism of Chinese Hamster Ovary cells in culture. Biotechnol Bioeng. 2009; 103: 592-608.
16. Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods. 1989; 125: 191-202.
17. Qu Z, Griffiths GL, Wegener WA, Chang C-H, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM. Development of humanized antibodies as cancer therapeutics. Methods. 2005; 36: 84-95.
18. Gauthier ER, Piché L, Lemieux G, Lemieux R. Role of bcl-xL in the control of apoptosis in murine myeloma cells. Cancer Res. 1996; 56: 1451-1456.
19. Kim, NS, Lee, GM. Overexpression of Bcl-2 inhibits sodium butyrate-induced apoptosis in Chinese hamster ovary cells resulting in enhanced humanized antibody production. Biotechnol Bioeng. 2000; 71: 184-193.
20. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi Y-X, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schoeber WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreef M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10: 375-388.
21. Paquette JC, Guerin PJ, Gauthier ER. Rapid induction of the intrinsic apoptotic pathway by L-glutamine starvation. J Cell Phys. 2005; 202: 912-921.
22. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009; 114: 3864-3871.
23. Rossi EA, Rossi DL, Stein R, Goldenberg DM, Chang CH. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res. 2010; 70: 7600-7609.
24. Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 2008; 68: 4819-4826.
25. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008; 68: 8384-8392.
26. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood. 2009; 113: 6161-6171.
27. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009; 114: 3864-3871.
28. Rossi EA, Rossi DL, Stein R, Goldenberg DM, Chang CH. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res. 2010; 70: 7600-7609.
29. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008; 68: 5282-5290.
30. Lattenmayer C, Loeschel M, Schriebl K, Steinfellner W, Sterovsky T, Trummer E, Vorauer-Uhl K, Müller D, Katinger H, Kunert R. Protein-free transfection of CHO host cells with an IgG-fusion protein: selection and characterization of stable high producers and comparison to conventionally transfected clones. Biotechnol Bioeng. 2007; 96: 1118-1126.
31. Sinacore MS, Charlebois TS, Harrison S, Brennan S, Richards T, Hamilton M, Scott S, Brodeur S, Oakes P, Leonard M, Switzer M, Anagnostopoulos A, Foster B, Harris A, Jankowski M, Bond M, Martin S, Adamson SR. CHO DUKX cell lineages preadapted to growth in serum-free suspension culture enable rapid development of cell culture processes for the manufacture of recombinant proteins. Biotechnol Bioeng. 1996; 52: 518-528.
32. Hartman TE, Sar N, Genereux K, Barritt DS, He Y, Burky JE, Wesson MC, Yun J, Tsurushita Y, Zhou W, Sauer PW. Derivation and characterization of cholesterol-independent non-GS NSO cell lines for production of recombinant antibodies. Biotechnol Bioeng. 2007; 96: 294-306.
33. Rosser MP, Xia W, Hartsell S, McCaman M, Zhu Y, Wang S, Harvey S, Bringmann P, Cobb RR. Transient transfection of CHO-K1-S using serum-free medium in suspension: a rapid mammalian protein expression system. Protein Expr Purif. 2005; 40: 237-243.
34. Pham PL, Perret S, Doan HC, Cass B, St-Laurent G, Kamen A, Durocher Y. Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency. Biotechnol Bioeng. 2003; 84: 332-342.
35. Derouazi M, Girard P, Van Tilborgh F, Iglesias K, Muller N, Bertschinger M, Wurm FM. Serum-free large-scale transient transfection of CHO cells. Biotech Bioeng. 2004; 87: 537-545.
36. Merten OW. Safety issues of animal products used in serum-free media. Dev Biol Stand. 1999; 99: 167-180.
37. Deng X, Gao F, Flagg, T, Anderson J, May WS. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol. 2006; 26: 4421-4434.
38. Maiuri MC, Toumelin GL, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G. Functional and physical interaction between Bcl-xL and a BH3-like domain in Beclin-1. EMBO J. 2007; 26: 2527-2539.
39. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK-1 mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008; 30: 678-688.